U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07020221) titled 'A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors' on May 26.
Brief Summary: This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Pancreatic Ductal Adenocarcinoma
Non Small Cell Lung Cancer
Colorectal Cancer
Solid Tumor, Adult
G12D Mutated KRAS
Intervention:
DRUG: VS-7375
VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor.
DRUG: Cetuximab
Cetuximab is a monoclonal antibody targeting the ep...